Difference between revisions of "Part:BBa K1993013"

Line 17: Line 17:
 
</html>
 
</html>
  
'''Figure 2. the mechanism of interaction between chemokine and chemokine receptor.'''
+
'''Figure 2. the mechanism of interaction between a chemokine and a chemokine receptor.'''
  
 
Under the circumstances of inflammation, various kinds of cytokines, including chemokines, are released by the lesions. Guided by the chemokines, cells expressing chemokine receptors move towards the lesions where they can function better.[2] What’s more, different diseases would release different pools of chemokines, which would recruit different effector cells. [https://static.igem.org/mediawiki/2016/2/2d/T--SYSU-MEDICINE--project-diseasse-table-chemokine.pdf See our disease table-chemokine]
 
Under the circumstances of inflammation, various kinds of cytokines, including chemokines, are released by the lesions. Guided by the chemokines, cells expressing chemokine receptors move towards the lesions where they can function better.[2] What’s more, different diseases would release different pools of chemokines, which would recruit different effector cells. [https://static.igem.org/mediawiki/2016/2/2d/T--SYSU-MEDICINE--project-diseasse-table-chemokine.pdf See our disease table-chemokine]
Line 31: Line 31:
  
  
'''Figure 3 purification of gene CXCR5'''
+
'''Figure 3 Purification of CXCR5'''
  
  
Line 39: Line 39:
 
</html>
 
</html>
  
'''Figure 4 Construction of expression vector of CXCR5'''
+
'''Figure 4 EF-1α-CXCR5'''
  
  
We introduced that plasmid into MSCs and tested the expression of CXCR5 in MSCs on the protein level (Figure 5)
+
We introduced that plasmid into MSCs and tested the expression of CXCR5 in MSCs on mRNA and protein level (Figure 5, Figure 6)
 +
 
 +
<html>
 +
<img src="https://static.igem.org/mediawiki/2016/7/74/T--SYSU-MEDICINE--2.2.3.png" style="width:400px"  ></a>
 +
 
 +
</html>
 +
 
 +
'''Figure 5. Relative mRNA Level of CXCR5.'''
  
 
<html>
 
<html>
Line 50: Line 57:
  
  
'''Figure 5. Western Blot Of CXCR5.'''
+
'''Figure 6. Western Blot Of CXCR5.'''
  
Then, we tested the chemotaxis of engineered MSCs by conducting Transwell assay against CXCL13. To our excitement, our engineered MSCs had improved their homing ability with chemokine receptor CXCR5(Figure 6).
+
Then, we tested the chemotaxis of engineered MSCs by conducting Transwell assay against CXCL13. To our excitement, our engineered MSCs had improved their homing ability with chemokine receptor CXCR5(Figure 7).
  
 
<html>
 
<html>
<img src="https://static.igem.org/mediawiki/2016/7/74/T--SYSU-MEDICINE--2.2.3.png" style="width:400px"  ></a>
+
<img src="https://static.igem.org/mediawiki/2016/5/5e/T--SYSU-MEDICINE--2.3.3.png" style="width:400px"  ></a>
  
 
</html>
 
</html>
  
'''Figure 6. transwell assay of CXCR5.'''
+
'''Figure 7. Transwell Assay of CXCR5.'''
  
 
==References==
 
==References==

Revision as of 18:51, 17 October 2016


CXCR5

Chemokine receptors are receptors found on the surface of certain cells that interact with chemokines. They have a 7-transmembrane (7-TM) structure and couple to G-protein for signal transduction within a cell. [1] (Figure 1) Following interaction with their specific chemokine ligands, chemokine receptors trigger a flux intracellular calcium (Ca2+) ions, initiate chemotaxis and guide the cell to a desired location. (Figure 2)

Figure 1. typical structure of a chemokine receptor.

Figure 2. the mechanism of interaction between a chemokine and a chemokine receptor.

Under the circumstances of inflammation, various kinds of cytokines, including chemokines, are released by the lesions. Guided by the chemokines, cells expressing chemokine receptors move towards the lesions where they can function better.[2] What’s more, different diseases would release different pools of chemokines, which would recruit different effector cells. See our disease table-chemokine

Based on the chemotaxis theory, in order to enhance the homing ability of our marvelous mesenchymal stem cells (MSCs) due to lack of enough chemokine receptors on their cell surface, we, SYSU-MEDICINE, had constructed a series of chemokine receptors that corresponding to different inflammatory diseases as far as possible. Among which, CXCL13 is a significant chemokine (CXCR5 is its chemokine receptor) in Delayed Type Hypersensitivity(DTH). See our disease table-chemokine

We acquired this gene from peripheral mononuclear blood cells (PMBCs) and purified it. (Figure 3) Then we constructed it under the control of EF-1α by Gateway technology. (Figure 4)


Figure 3 Purification of CXCR5


Figure 4 EF-1α-CXCR5


We introduced that plasmid into MSCs and tested the expression of CXCR5 in MSCs on mRNA and protein level (Figure 5, Figure 6)

Figure 5. Relative mRNA Level of CXCR5.


Figure 6. Western Blot Of CXCR5.

Then, we tested the chemotaxis of engineered MSCs by conducting Transwell assay against CXCL13. To our excitement, our engineered MSCs had improved their homing ability with chemokine receptor CXCR5(Figure 7).

Figure 7. Transwell Assay of CXCR5.

References

[1]Allen, Samantha J.; Crown, Susan E.; Handel, Tracy M. (2007-01-01). "Chemokine: receptor structure, interactions, and antagonism". Annual Review of Immunology. 25: 787–820.

[2] Griffith J W, Sokol C L, Luster A D. Chemokines and chemokine receptors: positioning cells for host defense and immunity.[J]. Annual Review of Immunology, 2014, 32(1):659-702.


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal XhoI site found at 31
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 973
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI.rc site found at 259
    Illegal SapI site found at 1050